Last reviewed · How we verify
QL1604
QL1604 is a small molecule drug that targets the SGLT2 receptor.
QL1604 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | QL1604 |
|---|---|
| Also known as | PD-1 monoclonal antibody |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
QL1604 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
Key clinical trials
- a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. (PHASE3)
- QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer (PHASE2, PHASE3)
- A Phase I Study of QL1604 for Advanced Solid Tumors (PHASE1)
- A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors (PHASE1)
- QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors (PHASE2)
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QL1604 CI brief — competitive landscape report
- QL1604 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI